Lyell Immunopharma, Inc. (LYEL)
12.20
-0.68
(-5.24%)
USD |
NASDAQ |
Sep 10, 16:00
12.20
0.00 (0.00%)
After-Hours: 16:25
Lyell Immunopharma Enterprise Value : 143.85M for Sept. 9, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 09, 2026 | 143.85M |
| September 08, 2026 | 159.06M |
| September 04, 2026 | 178.71M |
| September 03, 2026 | 177.54M |
| September 02, 2026 | 192.40M |
| September 01, 2026 | 182.34M |
| August 31, 2026 | 177.54M |
| August 28, 2026 | 182.45M |
| August 27, 2026 | 184.33M |
| August 26, 2026 | 188.77M |
| August 25, 2026 | 204.92M |
| August 24, 2026 | 187.37M |
| August 21, 2026 | 205.85M |
| August 20, 2026 | 201.64M |
| August 19, 2026 | 211.23M |
| August 18, 2026 | 211.93M |
| August 17, 2026 | 159.53M |
| August 14, 2026 | 168.88M |
| August 13, 2026 | 163.97M |
| August 12, 2026 | 174.03M |
| August 11, 2026 | 190.64M |
| August 10, 2026 | 177.78M |
| August 07, 2026 | 186.67M |
| August 06, 2026 | 174.97M |
| August 05, 2026 | 157.19M |
| Date | Value |
|---|---|
| August 04, 2026 | 160.70M |
| August 03, 2026 | 143.62M |
| July 31, 2026 | 145.25M |
| July 30, 2026 | 163.50M |
| July 29, 2026 | 145.96M |
| July 28, 2026 | 146.42M |
| July 27, 2026 | 145.72M |
| July 24, 2026 | 138.00M |
| July 23, 2026 | 141.51M |
| July 22, 2026 | 142.91M |
| July 21, 2026 | 149.23M |
| July 20, 2026 | 144.79M |
| July 17, 2026 | 154.14M |
| July 16, 2026 | 167.48M |
| July 15, 2026 | 176.14M |
| July 14, 2026 | 156.02M |
| July 13, 2026 | 177.78M |
| July 10, 2026 | 193.68M |
| July 09, 2026 | 198.36M |
| July 08, 2026 | 202.81M |
| July 07, 2026 | 214.74M |
| July 06, 2026 | 170.99M |
| July 02, 2026 | 171.22M |
| July 01, 2026 | 145.96M |
| June 30, 2026 | 171.22M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 11.44B |
| Oncolytics Biotech, Inc. | 95.42M |
| Sangamo Therapeutics, Inc. | 55.96M |
| Sarepta Therapeutics, Inc. | 2.583B |
| Anixa Biosciences, Inc. | 82.91M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -44.76M |
| Revenue (Quarterly) | 0.004M |
| Total Expenses (Quarterly) | 44.76M |
| EPS Diluted (Quarterly) | -1.916 |
| Gross Profit Margin (Quarterly) | -55.45K% |
| Profit Margin (Quarterly) | -1.12M% |
| Earnings Yield | -96.42% |
| Normalized Earnings Yield | -80.41 |